Potential nondopaminergic drugs for Parkinson's disease.
Silverdale
Monty A
MA
Manchester Movement Disorder Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.
Fox
S H
SH
Crossman
A R
AR
Brotchie
J M
JM
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001479:Basal Ganglia / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008959:Models, Neurological; D009434:Neural Pathways / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D018377:Neurotransmitter Agents / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D017981:Receptors, Neurotransmitter / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology
D000978:Antiparkinson Agents; D018377:Neurotransmitter Agents; D017981:Receptors, Neurotransmitter; D007980:Levodopa